Review: chemokines in transplantation

Transplantation Reviews

Volumn 21, Issue 2, 2007, Pages 107-118

  Schadde, Erik ^a   Knechtle, Stuart J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CYCLOSPORIN; CYCLOSPORIN A; FINGOLIMOD; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MARAVIROC; MDX 1100; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CCR5; MONOCLONAL ANTIBODY CXCR3; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RANTES; RAPAMYCIN; REPERTAXIN; T 0906487; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIGEN PRESENTING CELL; ARTICLE; BRADYCARDIA; CARDIAC GRAFT REJECTION; CELL MIGRATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG POTENTIATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE MIGRATION; MEMORY CELL; MONOTHERAPY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; ORGAN TRANSPLANTATION; PSORIASIS; RECEPTOR BLOCKING; REGULATORY T LYMPHOCYTE; RETINA MACULA EDEMA; ULCERATIVE COLITIS;

EID: 34249683904     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2007.03.004     Document Type: Article

References (107)

1. Pattison J., Nelson P.J., Huie P., et al. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet 343 (1994) 209-211
2. Gao Z., and Metz W.A. Unraveling the chemistry of chemokine receptor ligands. Chem Rev 103 (2003) 3733-3752
3. Luster A.D., Alon R., and von Andrian U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immun 6 (2005) 1182-1190
4. von U.H. Cellular traffic in lymph nodes. Nat Rev Immunol 3 (2003) 867-878
5. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354 (2006) 610-621
6. Kapoor A., Morita K., Engeman T.M., et al. Early expression of interferon-gamma inducible protein 10 and monokine induced by interferon-gamma in cardiac allografts is mediated by CD8+ T cells. Transplantation 69 (2000) 1147-1155
7. Melter M., Exeni A., Reinders M.E., et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 104 (2001) 2558-2564
8. Hauser I.A., Spiegler S., Kiss E., et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol 16 (2005) 1849-1858
9. Hu H., Aizenstein B.D., Puchalski A., et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 4 (2004) 432-437
10. Hancock W.W., Lu B., Gao W., et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 192 (2000) 1515-1520
11. Hancock W.W., Gao W., Csizmadia V., et al. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 193 (2001) 975
12. Miura M., Morita K., Kobayashi H., et al. Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 167 (2001) 3494-3504
13. Belperio J.A., Keane M.P., Burdick M.D., et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 169 (2002) 1037-1049
14. Belperio J.A., Keane M.P., Burdick M.D., et al. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol 171 (2003) 4844-4852
15. Zhang Z., Kaptanoglu L., Tang Y., et al. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. Gastroenterology 126 (2004) 809-818
16. Akashi S., Sho M., Kashizuka H., et al. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 80 (2005) 378-384
17. Medoff B.D., Wain J.C., Seung E., et al. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J Immunol 176 (2006) 7087
18. Sullivan K., Adams A., Nomura N., et al. In vivo consequences of CXCR3 blockade with small molecular antagonists. Presented at the Keystone Meeting on Chemokines, Snowbird, Utah, January 15-20 (2006)
19. Zerwes H.-G., Kovarik J., Streiff M.B., et al. Potent pharmacologic inhibitors of CXCR3 do not inhibit rat allograft rejection. Transplantation 82 Suppl 3 (2006) 599 [abstr]
20. Zerwes H.G., Kovarik J., Li J., et al. Allograft rejection in chemokine receptor CXCR3-deficient mice (abstract). Transplantation 82(1) Suppl 3 (2006) 599 [abstr]
21. Hazinedaroglu S.S.E., Kwun E., Roenneburg D., Fechner J., Sullivan K., Shiao L.L., et al. Graft survival in heterotopic heart transplant model across major histocompatibility barrier in mouse CXCR3 knock-out and human CXCX3 knock-in-mice. Transplantation 82(1) Suppl 3 (2006) 759 [abstr]
22. Goodarzi K., Goodarzi M., Tager A.M., et al. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immun 4 (2003) 965-973
23. Kwun J., Hu H., Roenneburg D., et al. Reduced recruitment of alloantigen specific T cells to heart grafts in CXCR3-/- recipient mice. Transplantation 82(1) Suppl 3 (2006) 425 [abstr]
24. Liu L., Huang D., Matsui M., et al. Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis. J Immunol 176 (2006) 4399-4409
25. Liu L., Callahan M.K., Huang D., et al. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol 68 (2005) 149-181
26. Segerer S., Nelson P.J., and Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11 (2000) 152-176
27. Fischereder M., Luckow B., Hocher B., et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 357 (2001) 1758-1761
28. Gao W., Faia K.L., and Csizmadia V. Beneficial effects of targetting CCR5 in allograft recipients. Transplantation 72 (2000) 1199
29. Abdi R., Smith R.N., Makhlouf L., et al. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 51 (2002) 2489-2495
30. Solomon M.F., Kuziel W.A., Mann D.A., et al. The role of chemokines and their receptors in the rejection of pig islet tissue xenografts. Xenotransplantation 10 (2003) 164-177
31. Luckow B., Joergensen J., Chilla S., et al. Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice. Eur J Immunol 34 (2004) 2568-2578
32. Schroppel B., Zhang N., Chen P., et al. Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways. J Am Soc Nephrol 15 (2004) 1853
33. Yun J.J., Whiting D., Fischbein M.P., et al. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 109 (2004) 932
34. Yi S., Ouyang L., Ha H., et al. Involvement of CCR5 signaling in macrophage recruitment to porcine islet xenografts. Transplantation 80 (2005) 1468
35. Amano H., Bickerstaff A., Orosz C.G., et al. Absence of recipient CCR5 promotes early and increased allospecific antibody responses to cardiac allografts. J Immunol 174 (2005) 6499-6508
36. Grone H.J., Weber C., Weber K.S., et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. Faseb J 13 (1999) 1371-1383
37. Nozaki A., Amano H., Toma H., et al. Antibody mediated rejection of cardiac allografts in the absence of CCR5. Transplantation 82(1) Suppl 3 (2006) 134 [abstr]
38. Bickerstaff A.A., Pelletier R.P., Nozaki T., et al. A novel murine model of acute humoral rejection in renal allografts recapitulates clinical histopathology. Transplantation 82(1) Suppl 3 (2006) 127 [abstr]
39. Idemyor V. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies?. HIV Clin Trials 6 (2005) 272-277
40. Napier C., Sale H., Mosley M., et al. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol 71 (2005) 163-172
41. Fechner J.H., Hazinedaroglu A., Crumbaugh A.J., et al. Combined use of a S1P receptor agonist and a CCR5 antagonist leads to renal allograft prolongation in non-human primates. Transplantation 82(1) Suppl 3 (2006) 609 [abstr]
42. Nansen A., Christensen J.P., Andreasen S.O., et al. The role of CC chemokine receptor 5 in antiviral immunity. Blood 99 (2002) 1237-1245
43. Lim J.K., Glass W.G., McDermott D.H., et al. CCR5: no longer a "good for nothing" gene-chemokine control of West Nile virus infection. Trends Immunol 27 (2006) 308-312
44. Boring L., Gosling J., Cleary M., et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
45. Izikson L., Klein R.S., Charo I.F., et al. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 192 (2000) 1075-1080
46. Peters W., Scott H.M., Chambers H.F., et al. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 98 (2001) 7958-7963
47. Boring L., Gosling J., Chensue S.W., et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100 (1997) 2552-2561
48. Kruger B., Schroppel B., Ashkan R., et al. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 13 (2002) 2585-2589
49. Abdi R., Tran T.B., Sahagun-Ruiz A., et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13 (2002) 754-758
50. Belperio J.A., Keane M.P., Burdick M.D., et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 108 (2001) 547-556
51. Lee I., Wang L., Wells A.D., et al. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 171 (2003) 6929-6935
52. Rao A.R., Quinones M.P., Garavito E., et al. CC chemokine receptor 2 expression in donor cells serves an essential role in graft-versus-host disease. J Immunol 171 (2003) 4875-4885
53. Abdi R., Means T.K., Ito T., et al. Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol 172 (2004) 767-775
54. Solomon M.F., Kuziel W.A., and Simeonovic C.J. The contribution of chemokines and chemokine receptors to the rejection of fetal proislet allografts. Cell Transplant 13 (2004) 503-514
55. Schroppel B., Zhang N., Chen P., et al. Role of donor-derived monocyte chemoattractant protein-1 in murine islet transplantation. J Am Soc Nephrol 16 (2005) 444-451
56. Terwey T.H., Kim T.D., Kochman A.A., et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood 106 (2005) 3322-3330
57. Cheng X., Dai H., Liu Z., et al. Impaired generation but not maintenance of allospecific memory CD8 T-cells in MCP-1-deficient mice. Am J Transplant World Transplant Congress Boston, #172 (2006)
58. Augustine J.J., Siu D.S., Clemente M.J., et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 5 (2005) 1971-1975
59. Heeger P.S., Greenspan N.S., Kuhlenschmidt S., et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 163 (1999) 2267-2275
60. Cossarizza A., Ortolani C., Paganelli R., et al. CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: implications for T cell memory. Mech Ageing Dev 86 (1996) 173-195
61. Schaerli P., and Moser B. Chemokines: control of primary and memory T-cell traffic. Immunol Res 31 (2005) 57-74
62. Habicht A., Clarkson M.R., Yang J., et al. Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J Immunol 176 (2006) 36-42
63. Zhang Q., Chen Y., Fairchild R.L., et al. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. J Immunol 176 (2006) 770-777
64. Pearl J.P., Parris J., Hale D.A., et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5 (2005) 465-474
65. London C.A., Lodge M.P., and Abbas A.K. Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol 164 (2000) 265-272
66. Tang A.L., Bingaman A.W., Kadavil E.A., et al. Generation and functional capacity of polyclonal alloantigen-specific memory CD4 T cells. Am J Transplant 6 (2006) 1275-1284
67. Mazo I.B., Honczarenko M., Leung H., et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 22 (2005) 259-270
68. Becker T.C., Coley S.M., Wherry E.J., et al. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 174 (2005) 1269-1273
69. Chen D., and Bromberg J.S. T regulatory cells and migration. Am J Transplant 6 (2006) 1518-1523
70. Iellem A., Mariani M., Lang R., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194 (2001) 847-853
71. Colantonio L., Iellem A., Sinigaglia F., et al. Skin-homing CLA+ T cells and regulatory CD25+ T cells represent major subsets of human peripheral blood memory T cells migrating in response to CCL1/I-309. Eur J Immunol 32 (2002) 3506-3514
72. Lee I., Wang L., Wells A.D., et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 201 (2005) 1037-1044
73. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
74. Mirenda V., Millington O., Lechler R.I., et al. Tolerant T cells display impaired trafficking ability. Eur J Immunol 35 (2005) 2146-2156
75. Ochando J.C., Homma C., Yang Y., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immun 7 (2006) 652-662
76. Szanya V., Ermann J., Taylor C., et al. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 169 (2002) 2461-2465
77. Kleinewietfeld M., Puentes F., Borsellino G., et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 105 (2005) 2877-2886
78. Bluestone J.A., and Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A 101 Suppl 2 (2004) 14622-14626
79. Apostolou I., and von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 199 (2004) 1401-1408
80. Wysocki C.A., Jiang Q., Panoskaltsis-Mortari A., et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 106 (2005) 3300-3307
81. Forster R., Schubel A., Breitfeld D., et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99 (1999) 23-33
82. Colvin B.L., Wang Z., Nakano H., et al. CXCL9 antagonism further extends prolonged cardiac allograft survival in CCL19/CCL21-deficient mice. Am J Transplant 5 (2005) 2104-2113
83. Wang L., Han R., Lee I., et al. Permanent survival of fully MHC-mismatched islet allografts by targeting a single chemokine receptor pathway. J Immunol 175 (2005) 6311-6318
84. Beckmann J.H., Yan S., Luhrs H., et al. Prolongation of allograft survival in ccr7-deficient mice. Transplantation 77 (2004) 1809-1814
85. Hopken U.E., Droese J., Li J.P., et al. The chemokine receptor CCR7 controls lymph node-dependent cytotoxic T cell priming in alloimmune responses. Eur J Immunol 34 (2004) 461-470
86. Garrod K.R., Chang C.K., Liu F.C., et al. Targeted lymphoid homing of dendritic cells is required for prolongation of allograft survival. J Immunol 177 (2006) 863-868
87. Troncoso P., Stepkowski S.M., Wang M.E., et al. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine. Transplantation 67 (1999) 145-151
88. Kawaguchi T., Hoshino Y., Rahman F., et al. FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A. Transplant Proc 28 (1996) 1062-1063
89. Hoshino Y., Suzuki C., Ohtsuki M., et al. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc 28 (1996) 1060-1061
90. Chiba K., Yanagawa Y., Masubuchi Y., et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160 (1998) 5037-5044
91. Mandala S., Hajdu R., Bergstrom J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
92. Matloubian M., Lo C.G., Cinamon G., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 (2004) 355-360
93. Allende M.L., Dreier J.L., Mandala S., et al. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 279 (2004) 15396-15401
94. Sanchez T., Estrada-Hernandez T., Paik J.H., et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 278 (2003) 47281-47290
95. Budde K., Schmouder R.L., Brunkhorst R., et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13 (2002) 1073-1083
96. Tedesco-Silva H., Mourad G., Kahan B.D., et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 77 (2004) 1826-1833
97. Kappos L., Antel J., Comi G., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355 (2006) 1124-1140
98. Reichel C.A., Khandoga A., Anders H.J., et al. Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue. J Leukoc Biol 79 (2006) 114-122
99. Belperio J.A., Keane M.P., Burdick M.D., et al. CXCR2/CXCR2 ligand biology during lung transplant ischemia-reperfusion injury. J Immunol 175 (2005) 6931-6939
100. Cugini D., Azzollini N., Gagliardini E., et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 67 (2005) 1753-1761
101. Bertini R., Allegretti M., Bizzarri C., et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 101 (2004) 11791-11796
102. Ysebaert D.K., De Greef K.E., De Beuf A., et al. T cells as mediators in renal ischemia/reperfusion injury. Kidney Int 66 (2004) 491-496
103. Adams A.B., Pearson T.C., and Larsen C.P. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 196 (2003) 147-160
104. Zhai Y., Shen X.D., Hancock W.W., et al. CXCR3+CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury. J Immunol 176 (2006) 6313-6322
105. Floto R.A., Macary P.A., Boname J.M., et al. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 314 (2006) 454-458
106. El-Sawy T., Belperio J.A., Strieter R.M., et al. Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 112 (2005) 320-331
107. Castellino F., Huang A.Y., Altan-Bonnet G., et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440 (2006) 890-895